TocilizumabV1, 2020, Analysis, bibRecord, 000067

Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.

Identifieur interne : 000067 ( 2020/Analysis ); précédent : 000066; suivant : 000068

Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.

Auteurs : Thomas Maldiney [France] ; Clémence Deschasse [France] ; Philip Bielefeld [France]

Source :

Ocular immunology and inflammation [ 1744-5078 ] ; 2020.

RBID : pubmed:30457413

Abstract

Purpose: To discuss the use of tocilizumab in mild to severe Graves' ophthalmopathy as corticosteroid-adjunctive therapy. Methods: Retrospective case reports.Results: Three patients with corticosteroid-resistant or advanced diplopia-associated Graves' ophthalmopathy were subsequently treated with monthly intravenous tocilizumab at a dose of 8 mg/kg. None reported a past or present history of dysthyroidism. The adjunction of interleukin-6-receptor monoclonal antibody treatment was associated with a significant improvement in ocular symptoms, notably diplopia and proptosis, and functional prognosis in all patients, with one relapse approximately two months after the end of the treatment.Conclusion: These clinical reports confirm the relative efficacy and tolerability profile of intravenous tocilizumab in severe or corticosteroid-resistant Graves' ophthalmopathy.

DOI: 10.1080/09273948.2018.1545914
PubMed: 30457413

Affiliations:

Links to Exploration step

pubmed:30457413

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.</title>
<author><name sortKey="Maldiney, Thomas" sort="Maldiney, Thomas" uniqKey="Maldiney T" first="Thomas" last="Maldiney">Thomas Maldiney</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Dijon Bourgogne University Hospital, Dijon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Internal Medicine, Dijon Bourgogne University Hospital, Dijon</wicri:regionArea>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Bourgogne</region>
<settlement type="city">Dijon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Deschasse, Clemence" sort="Deschasse, Clemence" uniqKey="Deschasse C" first="Clémence" last="Deschasse">Clémence Deschasse</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Ophthalmology, Dijon Bourgogne University Hospital, Dijon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Ophthalmology, Dijon Bourgogne University Hospital, Dijon</wicri:regionArea>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Bourgogne</region>
<settlement type="city">Dijon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bielefeld, Philip" sort="Bielefeld, Philip" uniqKey="Bielefeld P" first="Philip" last="Bielefeld">Philip Bielefeld</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Dijon Bourgogne University Hospital, Dijon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Internal Medicine, Dijon Bourgogne University Hospital, Dijon</wicri:regionArea>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Bourgogne</region>
<settlement type="city">Dijon</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:30457413</idno>
<idno type="pmid">30457413</idno>
<idno type="doi">10.1080/09273948.2018.1545914</idno>
<idno type="wicri:Area/PubMed/Corpus">000593</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000593</idno>
<idno type="wicri:Area/PubMed/Curation">000593</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000593</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000046</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000046</idno>
<idno type="wicri:Area/Ncbi/Merge">001C91</idno>
<idno type="wicri:Area/Ncbi/Curation">001C91</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001C91</idno>
<idno type="wicri:Area/Main/Merge">000067</idno>
<idno type="wicri:Area/Main/Curation">000067</idno>
<idno type="wicri:Area/Main/Exploration">000067</idno>
<idno type="wicri:Area/2020/Extraction">000067</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.</title>
<author><name sortKey="Maldiney, Thomas" sort="Maldiney, Thomas" uniqKey="Maldiney T" first="Thomas" last="Maldiney">Thomas Maldiney</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Dijon Bourgogne University Hospital, Dijon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Internal Medicine, Dijon Bourgogne University Hospital, Dijon</wicri:regionArea>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Bourgogne</region>
<settlement type="city">Dijon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Deschasse, Clemence" sort="Deschasse, Clemence" uniqKey="Deschasse C" first="Clémence" last="Deschasse">Clémence Deschasse</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Ophthalmology, Dijon Bourgogne University Hospital, Dijon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Ophthalmology, Dijon Bourgogne University Hospital, Dijon</wicri:regionArea>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Bourgogne</region>
<settlement type="city">Dijon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bielefeld, Philip" sort="Bielefeld, Philip" uniqKey="Bielefeld P" first="Philip" last="Bielefeld">Philip Bielefeld</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Dijon Bourgogne University Hospital, Dijon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Internal Medicine, Dijon Bourgogne University Hospital, Dijon</wicri:regionArea>
<placeName><region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Bourgogne</region>
<settlement type="city">Dijon</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Ocular immunology and inflammation</title>
<idno type="eISSN">1744-5078</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><i>Purpose</i>
: To discuss the use of tocilizumab in mild to severe Graves' ophthalmopathy as corticosteroid-adjunctive therapy. <i>Methods</i>
: Retrospective case reports.<i>Results</i>
: Three patients with corticosteroid-resistant or advanced diplopia-associated Graves' ophthalmopathy were subsequently treated with monthly intravenous tocilizumab at a dose of 8 mg/kg. None reported a past or present history of dysthyroidism. The adjunction of interleukin-6-receptor monoclonal antibody treatment was associated with a significant improvement in ocular symptoms, notably diplopia and proptosis, and functional prognosis in all patients, with one relapse approximately two months after the end of the treatment.<i>Conclusion</i>
: These clinical reports confirm the relative efficacy and tolerability profile of intravenous tocilizumab in severe or corticosteroid-resistant Graves' ophthalmopathy.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Bourgogne</li>
<li>Bourgogne-Franche-Comté</li>
</region>
<settlement><li>Dijon</li>
</settlement>
</list>
<tree><country name="France"><region name="Bourgogne-Franche-Comté"><name sortKey="Maldiney, Thomas" sort="Maldiney, Thomas" uniqKey="Maldiney T" first="Thomas" last="Maldiney">Thomas Maldiney</name>
</region>
<name sortKey="Bielefeld, Philip" sort="Bielefeld, Philip" uniqKey="Bielefeld P" first="Philip" last="Bielefeld">Philip Bielefeld</name>
<name sortKey="Deschasse, Clemence" sort="Deschasse, Clemence" uniqKey="Deschasse C" first="Clémence" last="Deschasse">Clémence Deschasse</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000067 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000067 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:30457413
   |texte=   Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i   -Sk "pubmed:30457413" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a TocilizumabV1

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

Serveur d'exploration Tocilizumab

Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.

Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Tocilizumab
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.